恩帕吉菲
达帕格列嗪
卡格列净
化学
肾葡萄糖重吸收
糖尿病
2型糖尿病
2型糖尿病
重症监护医学
药理学
内分泌学
医学
作者
Pradip D. Nahide,A. Ratnamala,Rakeshwar Bandichhor,Ch. V. A. Sasikala,Mallesh Beesu,Sayantan Biswas,Debjit Basu,Srinivas Achanta
出处
期刊:Synthesis
[Georg Thieme Verlag KG]
日期:2024-01-09
卷期号:56 (06): 906-943
被引量:3
标识
DOI:10.1055/s-0042-1751524
摘要
Abstract Diabetes mellitus, commonly referred to as diabetes, is a persistent medical condition that contributes to a significant global mortality rate and various associated complications in individuals. To address the needs of those diagnosed with type 2 diabetes, the pharmaceutical market offers a range of antidiabetic medications. Among these options, gliflozins stand out as highly efficacious therapeutic agents for the management of type 2 diabetes. These medications inhibit the function of sodium–glucose linked transporter (SGLT) enzymes in the kidneys, effectively halting the reabsorption of sugar and leading to a reduction in the overall glucose load within the bloodstream. This review aims at providing a comprehensive overview of the various syntheses for each of the gliflozin drugs reported in the literature and also summarizes the synthetic advancements in this area to date. 1 Introduction 2 Synthesis of Gliflozins 2.1 Canagliflozin 2.2 Dapagliflozin 2.3 Ipragliflozin 2.4 Empagliflozin 2.5 Luseogliflozin 2.6 Tofogliflozin 2.7 Ertugliflozin 2.8 Sotagliflozin 2.9 Licogliflozin 2.10 Remogliflozin 2.11 Henagliflozin 2.12 Bexagliflozin 2.13 Janagliflozin 2.14 Velagliflozin 2.15 Sergliflozin Etabonate 2.16 Enavogliflozin 3 Conclusion
科研通智能强力驱动
Strongly Powered by AbleSci AI